Forward Looking Insights...Okay another piece of speculation (guess). Matt Coffey gave an interview on Nov 10, 2022 to Biospace he suggested (reg. filings, type c meetings and fast-tracked designations) all in plurials.
So There is much much more i.e. licensing deal imminent. https://www.biospace.com/article/following-promising-data-oncolytics-plans-to-move-pancreatic-cancer-therapeutic-into-phase-iii/
Coffey said the next six to eight months will be exciting for Oncolytics due to its performance in other areas, as well. He anticipates poster presentations of data from the BRACELET-1 study in metastatic breast cancer patients in collaboration with Merck Serono and Pfizer, as well as data from a collaboration with Chinese partner Adlai Nortye.
“I think all of this sets us up for regulatory filings, Type C meetings and hopefully, Fast Track breakthrough designations," Coffey said, adding that Oncolytics is hoping to get a partnership in place next year to expedite the development and get the medicine to patients sooner.